EVP & Pres, Periph Intervent Jeffrey Mirviss Sells 15,000 Shares of Boston Scientific Corp (BSX)
On January 4, 2024, Jeffrey Mirviss, EVP & Pres, Periph Intervent of Boston Scientific Corp (NYSE:BSX), executed a sale of 15,000 shares in the company. The transaction was filed with the SEC and can be found through this SEC Filing.
Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets a range of medical devices used in various interventional medical specialties, including interventional cardiology, peripheral interventions, cardiac rhythm management, electrophysiology, endoscopy, urology, pelvic health, and neuromodulation.
Over the past year, the insider has sold a total of 52,910 shares and has not made any purchases. The company's insider transaction history indicates a total of 36 insider sells and no insider buys over the same timeframe.
On the day of the sale, shares of Boston Scientific Corp were trading at $58.4, resulting in a market cap of $85.203 billion. The price-earnings ratio stood at 70.93, which is above the industry median of 30.29 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio was 1.13, with a GF Value of $51.62, indicating that Boston Scientific Corp was modestly overvalued according to GuruFocus's valuation model.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
